Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: A pathologic analysis

ArticleinKidney International 61(6):2201-9 · July 2002with15 Reads
DOI: 10.1046/j.1523-1755.2002.00374.x · Source: PubMed
Abstract
Acquired renal cystic disease (ARCD), renal adenoma (AD), and renal cell carcinoma (RCC) are more common in patients with end-stage renal disease (ESRD). However, the prevalence of these conditions in patients undergoing transplantation, and the clinical characteristics associated with their occurrence are unclear. At our institution, the majority of patients undergo an ipsilateral native nephrectomy at the time of transplantation, providing a unique opportunity to study the prevalence and pathology of ARCD, AD and RCC in ESRD. We retrospectively reviewed all consecutive nephrectomy pathology reports over a six year period. Demographic and clinical characteristics associated with these lesions were identified. Two hundred and sixty nephrectomy reports were reviewed: ARCD, AD, RCC and oncocytoma were found in 33%, 14%, 4.2% and 0.6% of cases, respectively. On multivariable analysis, ARCD was positively associated with male sex and longer dialysis duration and negatively associated with peritoneal dialysis. Similarly, AD was positively associated with male sex, longer dialysis duration and greater age. There was a trend for RCC cases to share similar associations although the small total number of cases precluded findings of statistical significance. By pathologic analysis, renal tumors are more common in the pre-transplant ESRD population than previously reported (using radiologic methods). Our study also identifies risk factors for their occurrence. This may prove useful in designing screening studies for renal tumors in this patient population.
    • "This process is made even more difficult when concomitant acquired polycystic disease is present in the dialyzed kidney. This has a prevalence of 33% in patients with end-stage renal failure, particularly as these patients are at risk of malignancy, as the prevalence of renal cell cancers in this group is 4.2% [58]. Irrespective of the underlying disease, renal embolization is the first line emergency treatment if the bleeding is poorly tolerated clinically (Fig. 6). "
    [Show abstract] [Hide abstract] ABSTRACT: Several mechanisms predispose to bleeding in neoplastic disease. This is all the more serious as it often occurs on a background of medically vulnerable patients and the magnitude of the bleed may lead to hemorrhagic shock or acute respiratory distress as a result of hemoptysis. It often carries a poor prognosis, even if the acute episode has been controlled, as bleeding due to rupture of a tumor often indicates an advanced stage of the disease, and also because tumor rupture carries a risk of metastatic spread including peritoneal carcinomatosis. The risk of recurrent bleeding is also not insignificant. In most cases, endovascular hemostatic embolization is the first line palliative treatment. Copyright © 2015 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
    Full-text · Article · Jul 2015
    • "Indeed, when data were not available in the national registries, information was extracted from regional registries or from neighboring countries. In other studies, only one type of cancer was specifically studied [10, 11]. Moreover, unlike our study, they did not take into account the patients' clinical characteristics (comorbidities, BMI, serum albumin and hemoglobin) [5, 12, 13]. "
    [Show abstract] [Hide abstract] ABSTRACT: End-stage renal disease is a chronic and progressive pathology associated with several comorbidities, particularly diabetes. Indeed, diabetes is the first cause of end-stage renal disease and, in France, 42% of incident patients had diabetes in 2012. In the general population, diabetes is associated with increased cancer risk. The aim of this study was to examine the association between risk of cancer death and diabetes in a large French cohort of patients with end-stage renal disease. Data on all patients with end-stage renal disease who initiated dialysis in France between 2002 and 2009 were extracted from the Renal Epidemiology Information Network registry. The risk of dying by cancer was studied using the Fine and Gray model to take into account the competing risk of death by other causes. We analyzed 39,811 patients with end-stage renal disease. Their mean age was 67.7±15 years, 39.4% had diabetes and 55.3% at least one cardiovascular disease. Compared with the non-diabetic group, patients with diabetes were older and had more cardiovascular and respiratory comorbidities when they started dialysis. Conversely, fewer diabetic patients had also a tumor at the beginning of the renal replacement therapy. Cancer was indicated as the cause of death for 6.7% of diabetic and 13.4% of non-diabetic patients. The Fine and Gray multivariate analyses indicated that diabetes (HR=0.72 95% CI: [0.68-0.95], p<0.001) and also female gender, peritoneal dialysis, cardio-vascular disease and kidney transplantation were associated with decreased risk of death by cancer. In this French cohort of patients with end-stage renal disease, diabetes was not associated with a significant increased risk of dying from cancer. Studies on the incidence of cancer in patients with ESRD are now needed to evaluate the potential association between diabetes and specific malignancies in this population.
    Full-text · Article · May 2015
    • "Several factors could contribute to this higher prevalence, including depressed host immunity [6], impaired antioxidant defense mechanisms, increased synthesis of reactive oxygen [7] [8], and acquired renal cystic formation [9]. On the contrary, the biological behavior of RCC related to ESRD (ESRD-RCC) is generally reported to be less aggressive than that of RCC in the general population [3] [10]. However, the natural history and the prognosis of ESRD-RCC still remain unclear, with limited data from only a few small and noncomparative RCC series on dialysis patients or renal transplant patients or both [10]. "
    [Show abstract] [Hide abstract] ABSTRACT: Objectives: Previous studies have reported that elevated pretreatment C-reactive protein (CRP) levels are associated with poor outcome in various malignancies, including renal cell carcinoma (RCC), in the general population. However, there is no evidence of such an association in dialysis patients. Therefore, the aim of this study is to evaluate the prognostic significance of preoperative serum CRP levels in patients with RCC related to end-stage renal disease (ESRD) requiring hemodialysis (HD). Materials and methods: We evaluated 315 patients with ESRD requiring HD who underwent nephrectomy for RCC as the first-line treatment at our hospital from 1982 to 2013. Complete patient- and tumor-specific characteristics as well as preoperative CRP levels were assessed. We defined a serum CRP level >0.5mg/dl as elevated and divided these patients into 2 groups according to their preoperative CRP levels (CRP≤0.5 and >0.5mg/dl). The median follow-up was 51 months. Results: Preoperative CRP levels were elevated in 75 patients (23.8%). The Kaplan-Meier 5-year cancer-specific survival rates were 95.2% and 69.9% in patients with CRP levels≤0.5 and>0.5mg/dl, respectively (P<0.0001). Multivariate analysis identified preoperative CRP level as an independent predictor for cancer-specific survival, along with a pathological TNM stage and tumor grade (CRP>0.5: hazard ratio = 3.47; 95% CI: 1.35-9.18; P = 0.0098). The concordance index of multivariable base models increased after including the preoperative CRP levels. Conclusions: Preoperative serum CRP level might be an independent predictor of postoperative survival in patients with RCC related to ESRD requiring HD. Its routine use, together with the TNM classification and tumor grade, could allow better risk stratification and risk-adjusted follow-up of these patients.
    Full-text · Article · Aug 2014
Show more